Breast lesion detection and characterization at contrast-enhanced MR mammography: Gadobenate dimeglumine versus gadopentetate dimeglumine

Radiology

Volumn 237, Issue 1, 2005, Pages 45-56

  Pediconi, Federica ^a   Catalano, Carlo ^a   Occhiato, Rossella ^a   Venciitti, Fiammetta ^a   Fraioli, Francesco ^a   Napoli, Alessandro ^a   Kirchin, Miles A ^b   Passarieilo, Roberto ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Worldwide Medical Affairs   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; ECHOGRAPHY; FEMALE; HISTOLOGY; HUMAN; IMAGE SUBTRACTION; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE DIAGNOSIS; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING;

ADULT; AGED; BREAST; BREAST NEOPLASMS; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE;

EID: 25144488621     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2371041369     Document Type: Article

References (45)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Samuels JR, Haffty BG, Lee CH, Fischer DB. Breast conservation therapy in patients with mammographically undetected breast cancers. Radiology 1992;185:425-427.
3. Leibman AJ, Kruse B. Breast cancer: mammographic and sonographic findings after augmentation mammoplasty. Radiology 1990;174:195-198.
4. Jackson VP, Hendrick RE, Feig SA, Kopans DB. Imaging of the radiographically dense breast. Radiology 1993;188:297-301.
5. Mendelson EB. Evaluation of the postoperative breast. Radiol Clin North Am 1992; 30:107-138.
6. Stelling CB. MR imaging of the breast for cancer evaluation: current status and future directions. Radiol Clin North Am 1995;33:1187-1204.
7. Kelcz F, Santyr G. Gadolinium-enhanced breast MRI. Crit Rev Diagn Imaging 1995; 36:287-338.
8. Helbich TH. Contrast-enhanced magnetic resonance imaging of the breast. Eur J Radiol 2000;34:208-219.
9. Kuhl CK. MRI of breast tumors. Eur Radiol 2000;10:46-58.
10. Rankin SC. MRI of the breast. Br J Radiol 2000;73:806-818.
11. Kuhl CK, Schild HH. Dynamic image interpretation of the breast. J Magn Reson Imaging 2000;12:965-974.
12. Morris EA. Review of breast MRI: indications and limitations. Semin Roentgenol 2001;36:226-237.
13. Orel SG, Schnall MD. MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. Radiology 2001; 220:13-30.
14. Morris EA. Breast cancer imaging with MRI. Radiol Clin North Am 2002;40:443-466.
15. Piccoli CW. Contrast-enhanced breast MRl: factors affecting sensitivity and specificity. Eur Radiol 1997;7(suppl 5):281-288.
16. Boetes C, Barentsz JO, Mus RD, et al. MR characterization of suspicious breast lesions with a gadolinium-enhanced Turbo FLASH subtraction technique. Radiology 1994;193:777-781.
17. Stomper PC, Herman S, Klippenstein DL, et al. Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features. Radiology 1995;197:387-395.
18. Liu PF, Debatin JF, Caduff RF, Kacl G, Garzoli E, Krestin GP. Improved diagnostic accuracy in dynamic contrast-enhanced MRI of the breast by combined quantitative and qualitative analysis. Br J Radiol 1998; 71:501-509.
19. Khatri VP, Stuppino JJ, Espinosa MH, Pollack MS. Improved accuracy in differentiating malignant from benign mammographic abnormalities: a simple, improved magnetic resonance imaging method. Cancer 2001;92:471-478.
20. Cecil KM, Schnall MD, Siegelman ES, Lenkinski RE. The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy. Breast Cancer Res Treat 2001;68:45-54.
21. Nunes LW, Schnall MD, Orel SG. Update of breast MR imaging architectural interpretation model. Radiology 2001;219:484-494.
22. Gilles R, Zafrani B, Guinebretière JM, et al. Ductal carcinoma in situ: MR imaging-histopathologic correlation. Radiology 1995; 196:415-419.
23. Knopp MV, Bourne MW, Sardanelli F, et al. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine. AJR Am J Roentgenol 2003;181:663-676.
24. Foster MC, Helvie MA, Gregory NE, et al. Lobular carcinoma in situ or atypical lobular hyperplasia at core needle biopsy: is excisional biopsy necessary? Radiology 2004;231:813-819.
25. Spinazzi A, Lorusso V, Pirovano G, Kirchin M. Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine. Acad Radiol 1999;6:282-291.
26. Weinmann HJ, Laniado M, Muetzel W. Pharmacokinetics of Gd-DTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 1984;16:167-172.
27. Jones B, Kenward MG. Design and analysis of cross-over trials. 2nd ed. Monographs on statistics and applied probability. Boca Raton, Fia: Chapman & Hall/CRC, 2003.
28. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 2002;16:407-422.
29. de Haën C, Cabrini M, Akhnana L, Ratti D, Calabi L, Zozzini L. Gadobenate dimeglumine 0.5 M solution for injection (Multi-Hance): pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 1999;23(suppl 1): S161-S168.
30. Kirchin MA, Runge VM. Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 2003; 14:426-435.
31. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins: a new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 1997;32:780-796.
32. Colosimo C, Ruscalleda J, Korves M, et al. Detection of intracranial metastases: a multi-center, intra-patient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dose. Invest Radiol 2001;36:72-81.
33. Knopp MV, Runge VM, Essig M, et al. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology 2004;230:55-64.
34. Schneider G, Maas R, Schultze Kool L, et al. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol 2003; 38:85-94.
35. Volk M, Strotzer M, Lenhart M, et al. Renal time-resolved MR angiography: quantitative comparison of gadobenate dimeglumine and gadopentetate dimeglumine with different doses. Radiology 2001;220: 484-488.
36. Wyttenbach R, Gianella S, Alerci M, Braghetti A, Cozzi L, Gallino A. Prospective blinded evaluation of Gd-DOTA- versus Gd-BOPTA-enhanced peripheral MR angiography, compared with digital subtraction angiography. Radiology 2003;227:261-269.
37. Knopp MV, Giesel FL, von Tengg-Kobligk H, et al. Contrast-enhanced MR angiography of the run-off vasculature: intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine. J Magn Reson Imaging 2003;17:694-702.
38. Prokop M, Schneider G, Vanzulll A, et al. Contrast-enhanced MR angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology 2005;234:399-408.
39. Tilanus-Linthorst MM, Obdeijn IM, Bartels KC, de Koning HJ, Oudkerk M. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat 2000;63:53-60.
40. Stoutjesdijk MJ, Boetes C, Jager GJ, et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001; 93:1095-1102.
41. Warner E, Plewes DB, Shumak RS, et al. Comparison of breast magnetic resonance imaging, mammography and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001;19:3524-3531.
42. Fischer U, Kopka L, Grabbe E. Breast carcinoma: effect of pre-operative contrast-enhanced MR imaging on the therapeutic approach. Radiology 1999;213:881-888.
43. Gilles R, Guinebretiere JM, Shapeero LG, et al. Assessment of breast cancer recurrence with contrast-enhanced subtraction MR imaging: preliminary results in 26 patients. Radiology 1993;188:473-478.
44. Kinkel K, Helbich TH, Esserman LJ, et al. Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability. AJR Am J Roentgenol 2000;175:35-43.
45. Jacobs MA, Barker PB, Bluemke DA, et al. Benign and malignant breast lesions: diagnosis with multiparametric MR imaging. Radiology 2003;229:225-232.